Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 31, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Intravenous Tocilizumab Therapy can tackle Cytokine Storm in COVID-19 patients

Blood glucose regulation by an organ-based multi-level model

Pfizer Life Science Manager Job Recruitment – Apply Online

Intravenous Tocilizumab Therapy can tackle Cytokine Storm in COVID-19 patients
  • BiotechToday
  • World

Intravenous Tocilizumab Therapy can tackle Cytokine Storm in COVID-19 patients

bioxone October 24, 2020October 24, 2020

Chitra Roy, University of Calcutta

Since its emergence, COVID-19 has been constantly challenging the medical health system across the globe. COVID-19 infection is primarily accompanied by the aggressive inflammatory response with the release of excessive amounts of pro-inflammatory cytokines which are called ‘Cytokine Storm’. The immune response of the host to SARS-CoV-2 virus is extremely hyperactive leading to an extreme inflammatory reaction. Studies of cytokine profile from COVID-19 patients have shown that the ‘cytokine storm’ is directly related to massive alveolar damage, respiratory failure and multi-organ dysfunction. Patients showing these severe manifestations of the disease have elevated levels of Interleukin-6 (IL-6) which is a pro-inflammatory cytokine contributing to the cytokine storm. So, if IL-6 can be targeted, the disease progression can drastically reduce. 

Tocilizumab is the FDA approved recombinant humanized monoclonal antibody that can specifically target these IL-6 receptors. Tocilizumab therapy in COVID-19 patients in advanced disease cases showing severe symptoms has documented favourable outcomes. Both modes of administration i.e. intravenous (IV) and subcutaneous (SC) formulations have almost equal effects. However, the pharmacokinetic profiles of these two modes of administration differ significantly. Subcutaneous injections have a delayed yet sustained effect while Intravenous injections are more intensive but have a short-lived effect. 

But which of these two modes of tocilizumab administration is better to tackle the cytokine storm? To understand this, a research team in Brooklyn, USA made a comparative analysis of IV and SC tocilizumab therapy in COVID-19 patients to report which mode of administration can have better respiratory and clinical outcomes. 

Their study started with 125 COVID-19 positive patients with respiratory distress (peripheral oxygen saturation < 93% on room air) who were eligible for tocilizumab therapy. Among them, 82 patients had severe disease (receiving supplemental oxygen) and 43 of them were on mechanical ventilation and critically ill. However, the patients received standard treatment with hydroxychloroquine, azithromycin and a short course of corticosteroids. Only the mode of administration of tocilizumab differed. 65 patients received intravenous tocilizumab and 60 patients received subcutaneous tocilizumab. 

The researchers reported that they found divergent yet promising outcomes in COVID-19 patients for IV and SC administration. According to their report, after 3 days of tocilizumab therapy, 52% of patients from the IV group and 32% from SC group showed improved respiratory parameters. After 7 days, improvements differed. 52% of patients from IV and 28% from SC was reported. Their findings show improvements in respiratory parameters and lower in-hospital mortality in the patients who received IV tocilizumab therapy in comparison to those who received SC tocilizumab therapy. They also reported that the dose of corticosteroids was higher in patients who received IV tocilizumab which proved to benefit them by reducing mortality. Through their reports, they concluded that a combination of tocilizumab and corticosteroids has an additive effect in dealing with the cytokine storm in advanced COVID-19 cases and the IV mode of administration of tocilizumab is favoured over SC mode for better clinical results.

Also read: Structural and Functional Inhibition of CHIKV by CHK-124 and CHK-263mAbs

Reference: https://www.sciencedirect.com/science/article/pii/S1201971220321640

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged corticosteroids meaning covid-19 prevention covid-19 symptoms cytokine storm cytokine storm covid cytokine storm meaning cytokines hydroxychloroquine side effects inflammatory response after covid interleukin-6 covid interleukin-6 levels interleukin-6 levels in covid-19 range intravenous injection intravenous meaning pro-inflammatory cytokines subcutaneous injection tocilizumab injection

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Pfizer Life Science Manager Job Recruitment – Apply Online

bioxone October 24, 2020

-Shristi Sharma, Team bioXone Pfizer Life Science Manager Job Recruitment – Apply Online. Pfizer is hiring Graduate/Post-graduate/ Doctorate degree in life sciences candidates for the Medical Manager vacancy. Interested and eligible applicants can check out all of the details on the same below: Pfizer Vacancy Details Job Title: Medical Manager – GMAIST Job ID: 4795269 […]

Related Post

  • BiotechToday
  • World

Gene expression stability can be improved through hidden switches

bioxone January 31, 2021January 31, 2021

Ayooshi Mitra, Amity University, Kolkata Some organisms develop an internal switch that can remain hidden for very long or until it is switched on due to stress. Computer cell simulations have evolved over many generations. They disclose why some organisms maintain an un-used switch mechanism that turns on under severe stress, altering some of their […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

The Critical role of UGP2 – Pancreatic Ductal Adenocarcinoma Treatment

bioxone October 18, 2020October 17, 2020

Sumedha Guha, Techno India University A team of scientists recently found a metabolism-regulating protein UGP2 to play an essential role in pancreatic cancer growth and proliferation. Pancreatic Ductal Carcinoma or PDAC is the most common type of exocrine cancer that occurs in the pancreas with an occurrence rate of more than 90%. The majority of […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Neuroendocrine Prostate Cancer Cells with character “switching” capabilities!

bioxone January 16, 2021January 16, 2021

Richismita Hazra, Amity University Kolkata Cells often manifest reversible changes in their properties and phenotypes which is known as cellular plasticity. This is also termed lineage plasticity or lineage switching. Cancer cells use this phenomenon to adapt to stressful conditions and this leads to cancer progression. Neuroendocrine prostate cancer (NEPC) is an aggressive variant of […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy